Offer - Urjas Oil for just ₹ 1
Restofos 10 Mg Tablet is a commercial drug that is prescribed in the form of Tablet. Primarily, it is used for the treatment of Osteoporosis. Restofos 10 Mg Tablet also has some secondary and off-label uses. These are listed below.
The correct dosage of Restofos 10 Mg Tablet depends on the patient's age, gender, and medical history. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Restofos 10 Mg Tablet as well, which are listed below. Normally, these side effects of Restofos 10 Mg Tablet are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of Restofos 10 Mg Tablet is Mild for pregnant women and Unknown for women who are breastfeeding. In addition, Restofos 10 Mg Tablet's effects on the liver, heart and kidney are discussed below in the Restofos 10 Mg Tablet related warnings section.
Other conditions have been mentioned below in the Restofos 10 Mg Tablet contraindications section.
Besides this, Restofos 10 Mg Tablet may also have severe interaction with some medicines. Refer to the list below for further details.
In addition to the above precautions for Restofos 10 Mg Tablet, it is important to know that it is safe while driving, and is habit-forming.
Restofos 10 Mg Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult(Female) |
|
| Geriatric |
|
Is the use of Restofos 10 Mg Tablet safe for pregnant women?
Pregnant women may get mild side effects from Restofos.
Is the use of Restofos 10 Mg Tablet safe during breastfeeding?
Due to lack of research work on this topic, the side effects of Restofos for breastfeeding women are not known.
What is the effect of Restofos 10 Mg Tablet on the Kidneys?
Restofos has very mild side effects on the kidneys.
What is the effect of Restofos 10 Mg Tablet on the Liver?
Restofos may have severe effects on your liver, so do not take it without first consulting your doctor.
What is the effect of Restofos 10 Mg Tablet on the Heart?
Effects of Restofos on heart can be severe. It is not safe to use without doctor's advice.
If you are suffering from any of the following diseases, you should not take Restofos 10 Mg Tablet unless your doctor advises you to do so -
Is this Restofos 10 Mg Tablet habit forming or addictive?
Forming a habit of Restofos 10 Mg Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Restofos 10 Mg Tablet does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Restofos 10 Mg Tablet is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Restofos 10 Mg Tablet for mental disorders.
Interaction between Food and Restofos 10 Mg Tablet
Taking Restofos 10 Mg Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Restofos 10 Mg Tablet
Drinking alcohol while taking Restofos 10 Mg Tablet may lead to slight side effects. If you experience any side effects, contact your doctor.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Fosamax® (alendronate sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 345
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 121-123
